Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Designates UMN-0501 And Forodesine Hydrochloride Orphan Drugs

This article was originally published in PharmAsia News

Executive Summary

The Drug and Food Board of the Ministry of Health, Labor and Welfare designated UMN Pharma's UMN-0501 and MundiPharma's forodesine hydrochloride orphan drugs during a May 23 session.UMN-0501 is a pandemic influenza vaccine produced by recombinant protein expression. Compared to the current flu vaccines that are produced using eggs, UMN-0501 enables production in larger quantities and shorter time periods. It also has fewer side effects such as allergies, anaphylactic shock and Guilain-Barre syndrome. Forodesine hydrochloride is used to treat relapsing and intractable T-cell lymphoma, and adult T-cell leukemia. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel